X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Cancer Biomarkers

期刊標題檢索 CANCER BIOMARK 最新評論: Review Speed: 1.0 | Submission hit rate: 75.0 Focus on research dir... (2023-05-29)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Cancer Biomarkers]您好,您是該頁面的第 60369 位訪客。

期刊簡介
期刊名稱Cancer Biomarkers Cancer Biomarkers
LetPub Score
5.1
51 ratings
Rate

Reputation
4.1

Influence
5.2

Speed
8.5

期刊簡稱CANCER BIOMARK
ISSN1574-0153
E-ISSN1875-8592
h-index33
CiteScore
CiteScoreSJRSNIPCiteScore Rank
5.200.5790.450
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q2158 / 404
Category: Medicine
Subcategory: Genetics
Q2159 / 347
Category: Medicine
Subcategory: Cancer Research
Q3130 / 230

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion.

The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
官方網站http://www.iospress.nl/journal/cancer-biomarkers/
在線稿件提交https://www.editorialmanager.com/CBM
開放訪問No
出版商IOS Press
主題領域ONCOLOGY
出版國/地區NETHERLANDS
發行頻率隔月刊行
創刊年2005
每年文章數91每年文章數趨勢
黃金OA百分比6.10%
Web of Science 四分位
2023-2024
WOS Quartile: Q3

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ3209/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1574-0153%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: About 3.0 month(s)
競爭力 *來自作者的數據: About 50%
參考鏈接
相關期刊 【Cancer Biomarkers】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    NATURE REVIEWS DRUG DISCOVERYH-index: 289

    CiteScore: 137.40
    LANCETH-index: 700

    CiteScore: 148.10
    NEW ENGLAND JOURNAL OF MEDICINEH-index: 933

    CiteScore: 145.40
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    Nature Reviews Disease PrimersH-index: 48

    CiteScore: 76.70
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 93.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONH-index: 622

    CiteScore: 48.20
    World PsychiatryH-index: 70

    CiteScore: 64.10
    學科內最受檢索的期刊 頁面查看次數
    MEDICINE645704
    BIOMATERIALS600888
    Frontiers in Pharmacology502548
    BIOMEDICINE & PHARMACOTHERAPY498655
    JOURNAL OF ETHNOPHARMACOLOGY494545
    Journal of Materials Chemistry B476180
    Frontiers in Immunology461411
    COMPUTERS IN BIOLOGY AND MEDICINE420163
    COLLOIDS AND SURFACES B-BIOINTERFACES419538
    Frontiers in Oncology415875
  •  

    Cancer Biomarkers Cancer Biomarkers
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    下一頁    末頁  (頁
/5)
  [Cancer Biomarkers] 的評論撰寫評論
作者: 格洛丽亚瑞林


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-29 15:22:17 評論於
Review Speed: 1.0 | Submission hit rate: 75.0 Focus on research direction: Prognostic indicators; Experience sharing on liver cancer prognosis: 2023.3.18 submission---under review 2023.4.21 major revisions 8 | minor revisions 3 (pure clinical research, although there are many problems, they are all relatively easy to answer, did not require me to add data) 2023.5.08 resubmission---under review 2023.5.23 under review---process in decision 2023.5.28 acceptance
(0) 讚! | 格洛丽亚瑞林

作者: 英洁可爱吗


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-05 10:53:49 評論於
Review speed: 12.0 | Submission hit rate: 75.0
Emphasized research direction: tumor
Experience sharing: It is a very slow journal, with a turnaround time of 8 months to 1 year
(0) 讚! | 英洁可爱吗

作者: 降龙涵梅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-21 09:41:15 評論於
So slow, it has been under review for a week. Is it too urgent to withdraw the submission now? #slowreview#
(0) 讚! | 降龙涵梅

作者: Jill Will


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-14 16:38:02 評論於
I remember it was generated immediately
(0) 讚! | Jill Will

作者: Brady Whit


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-21 12:39:56 評論於
How long does it take to assign a number to the submitted manuscript?
(0) 讚! | Brady Whit

作者: 袈裟莉霞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-21 14:13:36 評論於
Review speed: 12.0 | Submission hit rate: 50.0
Sharing of experience: strongly discourage, 9 months for review, should have 1 rejection and 2 major revisions in the review comments, editor rejected after 1 month with very unprofessional reasons
(0) 讚! | 袈裟莉霞

作者: Jill Will


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-18 20:09:08 評論於
I was accepted, it took nearly 4 months in total
(0) 讚! | Jill Will

作者: 削月连胜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-07 23:21:58 評論於
How is your article coming along?
(0) 讚! | 削月连胜

作者: 削月连胜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-07 22:39:47 評論於
I have updated my schedule four times as well
(0) 讚! | 削月连胜

作者: Zachary DuBois


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-21 14:05:07 評論於
I am already three months old
(0) 讚! | Zachary DuBois

作者: Jill Will


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-21 12:28:17 評論於
It's been 2 months, but it's still the same, only time is passing by
(0) 讚! | Jill Will

作者: 灵犀颖萓


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-15 09:34:47 評論於
Research focus: Tumor biomarkers
Experience sharing: After submitting for nearly a month, the current status is "under review." What does that mean?
(0) 讚! | 灵犀颖萓

作者: 削月连胜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-23 11:01:47 評論於
How are things now?
(0) 讚! | 削月连胜

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 17:01:57 評論於
HIGHLIGHTS is just one of the requirements that authors must provide for journals under Elsevier. Not all journals include HIGHLIGHTS. The information provided by HIGHLIGHTS can help readers decide whether to read the paper further more quickly than reading the abstract
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 12:10:04 評論於
1. The study found that regular exercise can significantly reduce the risk of heart disease.
2. Participants who exercised at least three times a week had a 30% lower risk of developing heart disease.
3. Exercise was also shown to improve overall cardiovascular health and decrease inflammation in the body
(0) 讚! | 维尔娜菲茨杰拉德

作者: Darlene Pepys


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 20:54:56 評論於
What are the general requirements for the highlights section?
(0) 讚! | Darlene Pepys

作者: 修然小公主


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 12:15:50 評論於
When do we need the highlights section?
(0) 讚! | 修然小公主

作者: 静晨酱吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-06 18:05:54 評論於
My situation is the same
(0) 讚! | 静晨酱吖

作者: Daniel Margaret


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-09-16 23:21:52 評論於
Have you placed a bet?
(0) 讚! | Daniel Margaret

作者: 落英士魁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-07-23 13:11:37 評論於
Review speed: 6.0 Emphasis on research direction: Tumor Experience sharing: It took more than 4 months from submission to receiving the first review comments, with four reviewers, two minor revisions and two major revisions. The result was a rejection, with the editor suggesting I resubmit after making the necessary changes
(0) 讚! | 落英士魁

作者: 北风鸿振


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-07-19 22:58:34 評論於
Research focus: Tumors
Experience sharing: Submitted after March 26th, minor revision on June 15th, major revision on June 26th, accepted on July 18th, feeling pretty good about it
(0) 讚! | 北风鸿振

作者: 太枝mio


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-05-27 14:53:29 評論於
Can single gene bioinformatics without validation be submitted?
(0) 讚! | 太枝mio

作者: 志行可爱吗


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-03-22 09:24:18 評論於
Review speed: 6.0
Emphasis on research direction: tumor
Sharing experience: The review took five months, and the opinions of three reviewers were all minor issues. However, it was unexpectedly rejected in the end. It is a rubbish journal. I suggest being cautious about submitting to it
(0) 讚! | 志行可爱吗

作者: 孤云新曼


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-11-24 10:38:52 評論於
No clues... just click on the website link to check the status
(0) 讚! | 孤云新曼

作者: 岱宗思美


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-11-21 08:15:51 評論於
I recently reviewed a domestic bioinformatics article, with a one-month deadline. I took ten days and gave minor revisions, but I could see that another reviewer rejected it outright. It has been sitting with the editor for 20 days now, so the main issue seems to be the slow handling by the editor
(0) 讚! | 岱宗思美

首頁    上一頁    1    2    3    4    5    下一頁    末頁  (頁
/5)

開始撰寫 [Cancer Biomarkers] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*